Impel Pharmaceuticals (IMPL) Revenue & Revenue Breakdown
Impel Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$12.65M
Latest Revenue (Q)
$5.02M
Impel Pharmaceuticals Revenue by Period
Impel Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2022-12-31 | $12.65M | 1794.01% |
| 2021-12-31 | $668.00K | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Impel Pharmaceuticals generated $12.65M in revenue during NA 2022, up 1794.01% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Impel Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $5.02M | -23.71% |
| 2023-06-30 | $6.58M | 50.59% |
| 2023-03-31 | $4.37M | -12.70% |
| 2022-12-31 | $5.01M | 62.49% |
| 2022-09-30 | $3.08M | 9.95% |
| 2022-06-30 | $2.80M | 59.35% |
| 2022-03-31 | $1.76M | 204.85% |
| 2021-12-31 | $577.00K | 534.07% |
| 2021-09-30 | $91.00K | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Impel Pharmaceuticals generated $5.02M in revenue during Q3 2023, up -23.71% compared to the previous quarter, and up 179.20% compared to the same period a year ago.
Impel Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| IMPL | Impel Pharmaceuticals | $12.65M | $5.02M |
| HCWB | HCW Biologics | $2.84M | $618.85K |
| SNTI | Senti Biosciences | $2.56M | - |
| SONN | Sonnet BioTherapeutics | $147.81K | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| ANTX | AN2 Therapeutics | - | - |
| CYTO | Altamira Therapeutics | - | $52.73K |
| ACXP | Acurx Pharmaceuticals | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| CVKD | Cadrenal Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| MNPR | Monopar Therapeutics | - | - |
| CADL | Candel Therapeutics | - | - |
| ATXI | Avenue Therapeutics | - | - |
| PTIX | Protagenic Therapeutics | - | - |
| ENOB | Renovaro Biosciences | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| ELDN | Eledon Pharmaceuticals | - | - |
IMPL Revenue FAQ
What is Impel Pharmaceuticals’s yearly revenue?
Impel Pharmaceuticals's yearly revenue for 2022 was $12.65M, representing an increase of 1794.01% compared to 2021. The company's yearly revenue for 2021 was $668K, representing an increase of 100.00% compared to 2020. IMPL's yearly revenue for 2020 was $0, representing an increase of 100.00% compared to 2019.
What is Impel Pharmaceuticals’s quarterly revenue?
Impel Pharmaceuticals's quarterly revenue for Q3 2023 was $5.02M, a -23.71% decrease from the previous quarter (Q2 2023), and a 62.98% increase year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $6.58M, a 50.59% increase from the previous quarter (Q1 2023), and a 134.89% increase year-over-year (Q2 2022). IMPL's quarterly revenue for Q1 2023 was $4.37M, a -12.70% decrease from the previous quarter (Q4 2022), and a 148.55% increase year-over-year (Q1 2022).
What is Impel Pharmaceuticals’s revenue growth rate?
Impel Pharmaceuticals's revenue growth rate for the last 3 years (2020-2022) was 0%